Skip to content
Biodatica
Start free

Investigator

Wei R. Chen

UNIVERSITY OF OKLAHOMA · funded by NIGMS, NCI

Companies
1

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$4.4M

Summed across those awards.

First award
Apr 1, 2022

Latest May 15, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. P20

    Oklahoma Center of ImmunoEngineering (OCIE)

    $475k

    May 15, 2026NIGMSUNIVERSITY OF OKLAHOMANIH RePORTER · 11269423 (opens the source filing in a new tab)

  2. P20

    Oklahoma Center of ImmunoEngineering (OCIE)

    $2.5M

    May 15, 2026NIGMSUNIVERSITY OF OKLAHOMANIH RePORTER · 11269422 (opens the source filing in a new tab)

  3. P20

    Alteration and Renovation (A&R) Project

    $420k

    May 15, 2026NIGMSUNIVERSITY OF OKLAHOMANIH RePORTER · 11269430 (opens the source filing in a new tab)

  4. R01

    Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

    $489k

    Apr 1, 2022NCIUNIVERSITY OF OKLAHOMANIH RePORTER · 11052594 (opens the source filing in a new tab)

  5. R01

    Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

    $489k

    Apr 1, 2022NCIUNIVERSITY OF OKLAHOMANIH RePORTER · 11294281 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources